Sonus Pharmaceuticals Inc., which has fought to rebuild shareholder value following the failure of lead drug Tocosol Paclitaxel in a pivotal Phase III trial in September, is bolstering its clinical pipeline with the acquisition of Canadian biotech OncoGenex Technologies Inc. (BioWorld Today) Read More
